



ajanta pharma limited

Ajanta House,
Charkop, Kandivli West,
Mumbai 400 067
India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

4th September, 2017

To,

1. National Stock Exchange of India
Exchange Plaza, 5th Floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051
2. BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

**Sub.: Press Release - Entacapone Tablets approval from US FDA
(Scrip Codes: NSE – AJANTPHARM EQ & BSE – AJANTPHARM 532331)**

Dear Sir/Madam,

We are pleased to inform you that we have received the final approval for Entacapone Tablets from US FDA.

Press release issued by us for the same is enclosed for your information and records.

Thanking You,

Yours faithfully,

**Gaurang Shah
AVP – Legal & Company Secretary**

Encl.: Press Release

Press Release**Ajanta Pharma Announces US FDA Approval for
Entacapone Tablets**

Mumbai, India – (4th September, 2017) - Ajanta Pharma Limited, announces the receipt of final approval for Entacapone Tablets from US FDA*. It is a bioequivalent generic version of Comtan®¹ Tablets. Company will be launching the product shortly in 200mg strength tablets.

Entacapone Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 35 Abbreviated New Drug Application (ANDA) of which it has final approvals for 20 ANDAs; tentative approvals for 2 ANDAs; and 13 ANDAs are under review with US FDA.

About Ajanta Pharma

Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,500 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

For the financial year ended 31st March, 2017, Ajanta's consolidated revenue stood at Rs. 2,002 cr. (USD 305 million) and net profit stood at Rs. 507 cr. (USD 77 million). For the last 5 years, Ajanta Pharma has posted healthy performance with its consolidated revenue growing at 21% CAGR and net profit at 46% CAGR.

For more information on Ajanta Pharma Ltd., please visit www.ajantapharma.com and for Ajanta Pharma USA Inc., please visit www.ajantapharmausa.com

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

* *United States Food & Drug Administration*

¹ *Comtan® is a registered trademark of Orion Corporation*

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement